Which laboratory parameters are most used to monitor CKD-MBD and treatment impact?

• A. PTH, Calcium, Phosphate, and Vitamin D Levels
• B. Sodium, Potassium, Bicarbonate, and Chloride
• C. Glucose, HbA1c, and Lipids
• D. Creatinine, BUN, GFR, and Albumin

Answer: (A)

Monitoring CKD-MBD focuses on mineral metabolism markers: calcium, phosphate, PTH, and vitamin D. These elements directly reflect how chronic kidney disease disrupts bone-mineral balance and how treatment is affecting that balance.

Calcium and phosphate tell you about the immediate mineral levels in the blood. In CKD, phosphate clearance drops, often causing high phosphate levels, which can drive vascular calcification and disturb bone turnover. Calcium levels help you see whether calcium balance is being maintained; together with phosphate, they help you assess the risk of abnormal bone mineralization.

PTH shows how well the parathyroid glands are responding to the disturbances caused by CKD and low active vitamin D. If PTH is rising (secondary hyperparathyroidism), it signals that therapy may need adjustment—such as phosphate control, vitamin D supplementation, or a calcimimetic—to prevent bone disease and mineral imbalance.

Vitamin D status is crucial because kidney disease impairs the activation of vitamin D. Low vitamin D contributes to higher PTH and bone turnover problems, so measuring vitamin D helps guide supplementation and the use of active vitamin D analogs.

The other panels—electrolytes like sodium and potassium, bicarbonate, and chloride; glucose and lipids; or markers like creatinine, BUN, GFR, and albumin—are important for overall kidney function, fluid balance, metabolic disease risk, and nutrition, but they don’t specifically track CKD-MBD and the response to its treatments.